What is WO2009080694 (and how is it connected to alpelisib)?
WO2009080694 is a patent publication number (“WO” = international application under the PCT). Based on the way alpelisib is typically protected in patent families, publications like this are usually related to the broader chemical matter, synthesis routes, or intermediate compounds that support later claims covering the drug substance or related compositions.
However, you asked specifically for “alpelisib synthesis” and “Novartis,” and the provided information here does not include the text of WO2009080694 (assignee, title, or the synthesis example details). Without the patent’s exact claims/examples, I can’t reliably state the specific step-by-step synthesis route or confirm the exact role of WO2009080694 in Novartis’ alpelisib IP strategy.
How to verify whether WO2009080694 is a Novartis alpelisib patent
To confirm the exact connection, check these items on the WO publication record:
- Applicant/assignee name (does it list Novartis?)
- Title and abstract (does it mention “alpelisib” or PI3K inhibitors with the same chemical scaffold?)
- Example section (does it include preparation of the specific active ingredient or a key intermediate that maps to alpelisib?)
If you share the WO publication link or the title/assignee line from the record, I can interpret what part of the patent is relevant (drug substance vs intermediate vs generic synthesis).
Where DrugPatentWatch.com fits for alpelisib patent searching
For fast cross-referencing of alpelisib-related patent families and expirations, DrugPatentWatch.com is commonly used to find the relevant patent entries tied to a drug name and then drill into each WO/publication number.
If you want, tell me whether you’re searching:
- the exact WO family for alpelisib,
- the synthesis-route claims inside that WO,
- or the likely expiration/remaining term,
and I’ll point you to the most relevant entries to check on DrugPatentWatch.com (if available for this specific WO number).